-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Red Cat Holdings And 2 Other Penny Stocks Insiders Are Aggressively Buying
Red Cat Holdings And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones settled higher by around 175 points on Friday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Erasca
- The Trade: Erasca, Inc. (NASDAQ:ERAS) Director Arthur James Bristol bought a total of 20,000 shares at an average price of $4.14. To acquire these shares, it cost around $82.8 thousand.
- What's Happening: Erasca said first patient was dosed in HERKULES-1 Phase 1b trial evaluating ERAS-007 and ERAS-601 MAPKlamp combination in RAS/MAPK pathway-altered solid tumors.
- What Erasca Does: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
Cumberland Pharmaceuticals
- The Trade: Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Director Kenneth Krogulski acquired a total of 3,050 shares at an average price of $2.22. The insider spent around $6.78 thousand to buy those shares.
- What's Happening: Cumberland Pharmaceuticals, last month, posted a profit for its third quarter.
- What Cumberland Pharmaceuticals Does: Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.
Check This Out: Investor Fear Eases After US Stocks Record Gains
Don't forget to check out our premarket coverage here
Red Cat Holdings
- The Trade: Red Cat Holdings, Inc. (NASDAQ:RCAT) Director, Chairman of the Board, CEO Jeffrey M Thompson acquired a total of 3,300 shares at an average price of $0.79. To acquire these shares, it cost around $2.61 thousand.
- What's Happening: Red Cat recently reported wider-than-expected quarterly loss.
- What Red Cat Holdings Does: Red Cat Holdings Inc provides products, services, and solutions to the drone industry. It offers First Person View (FPV) video goggles to the drone industry, sells FPV drones and equipment, and provides various software and hardware solutions.
The Dow Jones settled higher by around 175 points on Friday. Investors, meanwhile, focused on some notable insider trades.
道瓊恩斯指數周五收盤上漲約175點。與此同時,投資者關注的是一些值得注意的內幕交易。
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
當內部人士買賣股票時,這表明了他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易員可以在他們的整體投資或交易決策中考慮這一因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是最近幾筆值得注意的細價股內幕交易。欲瞭解更多資訊,請查看Benzinga的內幕交易站臺。
Erasca
埃拉斯卡
- The Trade: Erasca, Inc. (NASDAQ:ERAS) Director Arthur James Bristol bought a total of 20,000 shares at an average price of $4.14. To acquire these shares, it cost around $82.8 thousand.
- What's Happening: Erasca said first patient was dosed in HERKULES-1 Phase 1b trial evaluating ERAS-007 and ERAS-601 MAPKlamp combination in RAS/MAPK pathway-altered solid tumors.
- What Erasca Does: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
- 行業: Erasca,Inc.(納斯達克:時代)董事亞瑟·詹姆斯·布裡斯托爾共買入2萬股平均價格為4.14美元。收購這些股份的成本約為82.8萬美元。
- 正在發生的事情:Erasca說,第一名患者在Herkules-1 1b期試驗中接受了劑量,評估了RAS/MAPK途徑改變的實體瘤中ERAS-007和ERAS-601 MAPKLAMP的組合。
- 埃拉斯卡做了什麼:Erasca Inc.是一家臨床階段的精確腫瘤學公司,專門致力於發現、開發和商業化RAS/MAPK通路驅動的癌症患者的治療方法。
Cumberland Pharmaceuticals
坎伯蘭製藥公司
- The Trade: Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Director Kenneth Krogulski acquired a total of 3,050 shares at an average price of $2.22. The insider spent around $6.78 thousand to buy those shares.
- What's Happening: Cumberland Pharmaceuticals, last month, posted a profit for its third quarter.
- What Cumberland Pharmaceuticals Does: Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription pharmaceutical products.
- 《貿易》: 坎伯蘭製藥公司。(納斯達克:CPIX)董事肯尼斯·克羅古爾斯基共購入3,050股平均價格為2.22美元。這位內部人士花了大約67.8萬美元購買了這些股票。
- 發生了什麼事?:坎伯蘭製藥公司上個月公佈了第三季度的利潤。
- 坎伯蘭製藥公司的業務:坎伯蘭製藥公司是一家專注於品牌處方藥產品的收購、開發和商業化的專業製藥公司。
Check This Out: Investor Fear Eases After US Stocks Record Gains
看看這個:美股錄得漲幅後投資者擔憂緩解
Don't forget to check out our premarket coverage here
別忘了在這裡查看我們的售前報道
Red Cat Holdings
紅貓控股
- The Trade: Red Cat Holdings, Inc. (NASDAQ:RCAT) Director, Chairman of the Board, CEO Jeffrey M Thompson acquired a total of 3,300 shares at an average price of $0.79. To acquire these shares, it cost around $2.61 thousand.
- What's Happening: Red Cat recently reported wider-than-expected quarterly loss.
- What Red Cat Holdings Does: Red Cat Holdings Inc provides products, services, and solutions to the drone industry. It offers First Person View (FPV) video goggles to the drone industry, sells FPV drones and equipment, and provides various software and hardware solutions.
- 《貿易》: 紅貓控股有限公司納斯達克:RCAT)董事,董事會主席,首席執行官傑弗裡·M·湯普森共購入3300股平均價格為0.79美元。收購這些股份的成本約為2.61萬美元。
- 發生了什麼事?:紅貓最近公佈的季度虧損超出預期。
- 紅貓控股是做什麼的:紅貓控股公司為無人機行業提供產品、服務和解決方案。它向無人機行業提供第一人稱觀看(FPV)視頻護目鏡,銷售FPV無人機和設備,並提供各種軟硬體解決方案。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧